

PHARMACOLOGICAL INVESTIGATION ON ANALGESIC AND ANTI-PYRETIC POTENTIAL OF B-AESCIN

Anubhav Dubey¹, Yatendra Singh², Jai Prakash Sonwani³, Prashant Mishra³, Vikas Bajpai¹ & Ravi Pratap Pandey¹

¹ Department of Pharmacology, Advance Institute of Biotech & Paramedical Sciences, Kanpur (U.P.) 209217

² Adarsh Vijendra Institute of Pharmaceutical Sciences, Shobhit University Gangoh, Saharanpur (U.P.) 247341

³ Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research Raebareli

Abstract

The present pharmacological exploration work was planned to investigate the pain relieving and antipyretic capability of β aescin (40 and 80 mg/kg, p.o.). Writhing activity produced acetic acid and Eddy's hot-plate model was utilized to assess pain relieving impact while antipyretic impact was surveyed against brewer's yeast incited pyrexia in rodent. Writhing reaction is essentially diminishes 49.73% while dormancy time of Eddy's hot-plate model is significantly higher 14.3417 ± 0.3477 at large of β aescin (80 mg/kg, p.o.). It also able to decrease anal temperature to $37.15 \pm 0.03^\circ$ in C brewer's yeast initiated pyrexia. All Preliminary outcome is significant when compare with Control. Primer trial result is obviously demonstrates that β aescin (80 mg/kg, p.o.) is having critical pain relieving and antipyretic potential.

Keywords:

β aescin, horse-chestnut, Analgesic, Antipyretic.

Introduction

Global market investigation shows that absolute piece of the overall industry of phytonutrients or nutraceuticals is 83 billion US \$. The worldwide market examiner trust in that in future it keeps on becoming because of overwhelming requests [1]. Plant based phytoextract and medicinal bioactive molecule are very popular due to its lesser number of side effects, high degree of compatibility and convenience [2], [3]. Today World Health Organization (WHO) is build out numerous approaches to advance utilization of home grown therapeutic compound [4]. As indicated by an investigation around more than 80 % populace of world relies upon customary plant-based prescriptions for their essential human services [5]. Despite its fame gigantic extent of home grown biosphere are staying to investigate [6, 7].

Nonsteroidal anti-inflammatory drugs are broadly recommend drugs for pain and fever suppression from recently conceived youngster to old patients [8, 9]. Primary issue with narcotic is physical and mental reliance. Narcotic is likewise dependable to cause medicate related resistance and compulsion [10]. While gastrointestinal disturbance and excessive touchiness response are noticeable with NSAIDS. Because of extreme harmful impact none of them is clearly useful [11, 12].

Aesculus hippocastanum (horse-chestnut) is situated in family Sapindaceae [13]. Its Seeds Extracts predominantly contains β aescin which is artificially identified with triterpenoid saponins. Its Extract approx. 30 individual constituents, normally known as β -aescin. This compound is pharmacologically useful [13, 14]. It shows wide range of action like antitumor, useful in venous deficiency, protective action on skin epithelium and anti-inflammatory. It also show strong cholesterol reducing as well as hepatoprotective action in animal [15-24].

In writing overview we find that there is a need logical writing identified with pharmacological and phytochemical imminent of β aescin. There is no logical writing are accessible on the pain relieving and antipyretic exercises of

Escin. In this manner, the current primer examination has been begun to finish up pain relieving and antipyretic action of β aescin in Wistar mice and rat.

Materials and methods

Drugs and Chemicals

β aescin (95%) for oral organization was acquired from Lepro Herbal Pvt. Ltd, Panipat (Haryana). Different substances, for example, Paracetamol (Dr. Reddy's Laboratory, Hyderabad, India), yeast powder (Sigma Aldrich, Bangalore, India), diclofenac sodium (Akums Drugs and Pharmaceuticals, Delhi, India) were utilized in the examination.

Experimental Animals

Grown-up albino rats (*Rattus norvegicus*) (150-250g) and Swiss albino mice (*Mus musculus*) (24-30 g) of both sex were utilized for the examination. Polypropylene confines were utilized to house (3 for each cage) the animal at a temperature of 28 ± 5 °C and 12 h day/night cycle. Hindustan Lever chow pellets were utilized to take care of the animal and water *ad libitum*. The animal were continued fasting for the time being preceding the experimentation and all the methods utilized in these examinations were endorsed by the Institutional Animal Ethics Committee. Institutional Animal Ethics Committee (1122/PO/Re/S/07/CPCSEA, 15.08.2018) endorsed all method utilized in the examination.

Writhing test

Acetic acid induced writhing modal was used to produce chemical nociception. Whole experimental study was divided in four groups of six ($n = 6$) mice in each. Healthy adult swiss albino mice, having weight range 30 to 35 gram were used in the study. Carboxyl methyl cellulose (CMC) 1% Suspension (1 ml/100 g body weight) was given to control batch. While standard batch got suspended diclofenac sodium (09 mg/kg) in CMC. Test bunch ATS1 and ATS2 got 40mg/kg and 80 mg/kg β aescin orally. Following thirty minutes 0.1 ml/10 g of 1% acetic acid (i.p.) infused to each batch. The quantity of squirms was determined for 15 min following five minutes acetic acid infusion [25, 26]. The evaluation of rate hindrance in writhing was done according to the accompanying equation

$$\% \text{ Inhibition} = ((\text{AWC} - \text{AWT}) / \text{AWC}) \times 100.$$

Where, AWC = Average number of writhing activity in control group, AWT = Average writhes in Treated group.

Hot plate method

Swiss albino mice having body weight between 30 to 40 gram of both genders were randomized into four batches of six in each ($n = 6$). Control Group got Carboxyl methyl cellulose 1% Suspension (1 ml/100 g body weight) while standard Group got suspended diclofenac sodium (09 mg/kg) in CMC. Test batch ATS1 and ATS2 got 40mg/kg and 80 mg/kg β aescin orally. Hot plate Temperature was kept up at 55°C to 56°C all through the examination. The animal were separately examined on the hot plate. The time either lacking or jumping happens was observed. Repeated observation for lacking or jumping was taken before and after 30 mint and 1 h, 2 h and 3 h following administration of the drugs to the particular batches. The cutoff time for mice was 15 sec to evade any injury^[25, 26].

Brewer's yeast induced pyrexia in albino wistar rats:

Twenty four grown-up albino rats (150-250g) of either sex were isolated haphazardly into four batches. Control Group got CMC 1% Suspension (1 ml/100 g body weight) while standard Group got Paracetamol (100 mg/kg) in CMC. Test batch ATS1 and ATS2 got 40mg/kg and 80 mg/kg β aescin orally.

5 % suspension of Brewer's Yeast in 0.9% saline was infused in back underneath the scruff of the neck in a portion of 10 ml/kg. Site of infusion is rubbed so as to spread the suspension underneath the skin. Before experimentation rectal temperature of rodents were recorded. Introductory rectal temperature was recorded. After 18h, animal that

presented an expansion of 0.3–0.5°C in rectal temperature were chosen. Rectal temperature was recorded by computerized thermometer 30 min previously and 0.5, 1, 2, 3, 4, 5 and 6 h after mentioned treatments [25, 27].

Statistical analysis

The measurable investigation was finished utilizing Graphpad Prism 8.0, which is financially accessible. Informative data were recorded as Mean \pm S.E.M. Bonferroni's ANOVA test is used to evaluate significance of differences within batches. When $P < 0.05$ then it is assumed statistically significant.

Result and discussion

In the present research proposal, an endeavour exertion has been made to assess the effectiveness of β aescin (40 mg/kg and 80 mg/kg) in pyrexia and nociception. β aescin (80mg/kg) is significantly effective in hindering perception of nociception produced by different analgesia models (Table 1 and 2). The result is further confirm by graph (Fig.1).

The Result of Brewer's yeast induced pyrexia model is clearly demonstrate that β aescin (80mg/kg) also having stringantipyretic potential (Table 3 and Fig. 2).

The intraperitoneally administered 1% suspension of acetic acid causes strong painful response in the control batch, with (90.17 \pm 2.07) abdominal contortions (Table 1). At both high and low dosages β aescin shows decrease in number of squirming's (67.50 \pm 6.85 and 31.50 \pm 3.42, respectively) when compare with standard (41.30 \pm 0.648). Animal treated with ATS (80 mg/kg) significantly lower writhing caused by acetic acid by 49.73% while standard drug Diclofenac sodium (9 mg/kg) reduced contortions by 52.9 % (Fig. 1).

After ATS (40 and 80 mg/kg) treatment, outcomes from Eddy's Hot plate shows that β aescin (80 mg/kg) significantly reduced pain at 120 min as compared to control. Increase in mean response time by diclofenac in the standard group was somewhat more (14.56 \pm 0.289s) than high dose (14.21 \pm 0.175s) of β aescin (80 mg/kg). We observed a dose dependent increase in latency of response in the Eddy's hot-plate method.

β aescin (80 mg/kg) is extremely compelling in restraining ascend in body temperature level by Brewer's Yeast (Table 3). Both Paracetamol (100 mg/kg) and ATS 80 mg/kg starts to show compelling antipyretic action after 1h of post dosing. ATS (80mg/kg) significantly decreases rectal temperature (37.26 \pm 0.026 °C) of the rat as compared to the control group (39.26 \pm 0.019°C). ATS (80mg/kg) and Paracetamol (100 mg/kg) are effectively suppressed rat body temperature up to 4 h after administration (Fig. 2).

Non-steroidal anti-inflammatory drugs (NSAIDS) are extensively used due to their analgesic, antipyretic and inflammatory action. Popular NSAIDS having very Sevier side effects like gastrointestinal disturbance with ulceration, hypersensitivity reaction, headache, increase risk of heart attack and stroke. Researcher all over universe are exceptionally worried to grow least poisonous, more advantageous and best option in contrast to famous NSAIDS [28]. In the current primer examination our goal is to assess the capability of β aescin as a pain relieving and antipyretic atom.

Creature study recommends that β aescin have solid pain relieving and antipyretic action. Analgesics and hostile to pyretic impact of β aescin might be because of concealment of prostaglandin and Arachidonic corrosive pathway. These outcomes might be used in the further explanation of the pain relieving and antipyretic capability of Escin. Further examination is required to investigate the real components associated with its antipyretic properties.

TABLE 1: POTENTIAL OF B AESCINON ACETIC ACID INDUCED NOCICEPTION IN MICE

Treatment Dose mg/kg	No. of writhing per 15 minute	Percentage (%) of Inhibition
Control	90.17± 2.07	-----
Diclofenac (09mg/Kg)	43.67±3.59*	51.56%
ATS1 (40mg/kg)	67.50±6.85	25.14%
ATS2 (80 mg/kg)	31.50 ±3.42*	65.06%

Qualities are organized as Mean ± SEM (n=6), the outcome were broke down by one way ANOVA followed by Bonferroni's Test, *P<0.05 contrast with control gathering, SEM= Standard Error mean, ATS= β aescin Test Sample

TABLE 2: ANALGESIC POTENTIAL OF B AESCININ MICE WITH HOT PLATE PROCEDURE

Treatment	Reaction time in seconds at different time interval				
	0min	30 min	1 h	2 h	3 h
Control	4.85±0.159	4.64±0.154	4.77±0.311	4.31±0.271	5.66±0.211
Diclofenac (09mg/Kg)	5.31 ± 0.183	13.80 ±0.307*	14.41±0.336*	15.11 ± 0.287*	14.56±0.289*
ATS1 (40mg/kg)	5.44±0.120	9.13±0.307	10.25±0.339*	12.17±0.311*	11.051±0.345*
ATS2 (80 mg/kg)	6.13±0.245	11.32±0.203*	13.84±0.243*	14.41±0.348*	14.21±0.175*

Values are tabulated as Mean ± SEM (n=6), the result were analyzed by one way ANOVA followed by Bonferroni's Test, *P<0.05 compare to control group, SEM= Standard Error mean, ATS= β aescin Test Sample

TABLE 3: ANTIPYRETIC POTENTIAL OF B AESCINON BREWER'S YEAST MEDIATED PYREXIA IN RAT

Treatment	Mean rectal temp. recordings after 18 h of Brewer's yeast injection in °C (% Decrease in Temp.)						
	0h	19h	20h	21h	22h	23h	24 h
Control	37.16 ±0.049	39.38 ±0.027	39.36 ±0.022 (0.06%)	39.31 ±0.019 (0.28%)	39.26 ±0.019 (0.44%)	39.18 ±0.027 (0.70%)	39.04 ±0.02 (0.80%)
PCM (100mg/kg)	37.19 ±0.023	39.24 ±0.041	37.95 ±0.037 (3.28%)	37.85* ±0.034 (3.54%)	37.57* ±0.026 (4.25%)	37.49* ±0.026 (4.9%)	37.25* ±0.031 (5.07%)
ATS1 40mg/kg	37.17 ±0.049	39.44 ±0.053	38.78 ±0.148 (1.6%)	38.68 ±0.022 (1.9%)	38.53 ±0.027 (2.3%)	38.34 ±0.024 (2.7%)	38.10 ±0.029 (3.99%)
ATS2 80mg/kg	37.05 ±0.044	39.23 ±0.069	37.55* ±0.025 (4.28%)	37.42* ±0.025 (4.61%)	37.26* ±0.026 (5.02%)	37.15* ±0.028 (5.30%)	37.1* ±0.025 (5.37%)

Values are tabulated as Mean \pm SEM ($n=6$), the result were analyzed by one way ANOVA followed by Bonferroni's Test, * $P<0.05$ compare to control group, SEM= Standard Error mean, ATS= β aescin Test Sample, PCM = Paracetamol.




FIG. 1: PROTECTIVE EFFECT OF β AESCIN WITH EDDY'S HOT PLATE




Fig. 2: Potential of β aescin on Brewer's Yeast Induced Pyrexia in Rat

Conflict of interest statement

Acknowledgements

This research project was supported by management of Advance Institute of biotech & paramedical sciences, Kanpur India.

References

1. WHO (World Health Organization) (2011) The World Traditional Medicines Situation, in Traditional medicines: Global Situation, Issues and Challenges. Geneva 3:1–14
2. Pal SK, Shukla Y. Herbal medicine: current status and the future Asian Pac J Cancer Prev. 2003 Aug-Dec;4(4):281-8. [PMID: 14728584]
3. Gupta LM and Raina R (1998). Side effects of some medicinal plants. Current Science, 75, 897-900.
4. Kamboj VP (2000). Herbal Medicine. Current Science, 78, 35-9.
5. Si-Yuan Pan, Shu-Feng Zhou, Si-Hua Gao, Zhi-Ling Yu, Shuo-Feng Zhang *et al.* New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics Evid Based Complement Alternat Med. 2013; 2013: 627375. [PMCID: PMC3619623], [PMID: 23634172]
6. Allkin B. Useful Plants – Medicines: At Least 28,187 Plant Species are Currently Recorded as Being of Medicinal Use. State of the World's Plants 2017. London (UK): Royal Botanic Gardens, Kew; 2017 [PMID: 29144713]
7. Pan S.-Y., Zhou S.-F., Gao S.-H., Yu Z.-L., Zhang S.-F., Tang M.-K., et al. (2013). New perspectives on how to discover drugs from herbal medicines: cam's outstanding contribution to modern therapeutics. Evid. Based Complement. Altern. Med. 2013:627375.
8. Bidaut-Russell M, Gabriel SE. Adverse gastrointestinal effects of NSAIDs: consequences and costs Best Pract Res Clin Gastroenterol. 2001 Oct;15(5):739-53. [PMID: 11566038]
9. Berde CB1, Sethna NF. Analgesics for the treatment of pain in children. N Engl J Med. 2002 Oct 3;347(14):1094-103 [PMID: 12362012]
10. Benyamin R., Trescot A.M., Datta S. et al. Opioid complications and side effects. Pain Physician. 2008. Mar; 11(2 Suppl): S105–20. [PMID: 18443635]
11. Sostres C1, Gargallo CJ, Arroyo MT, Lanás A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010 Apr;24(2):121-32.
12. Duthie DJ, Nimmo WS Adverse effects of opioid analgesic drugs. Br J Anaesth. 1987 Jan;59(1):61-77
13. Sirtori CR. Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res. 2001 Sep;44(3):183-93.
14. Pietta P, Mauri P, Maffei Facino R, Carini M. High-performance liquid Chromatographic analysis of β -aescin. J Chromatogr. 1989;478:259–263
15. Dworschak E, Antal M, Bíró L, Regöly-Mérei. A Medical activities of Aesculum hippocastanum (horse chestnut) saponins. Adv Exp Med Biol. 1996;404:471–474
16. Fu F, Hou Y, Jiang W, Wang R and Liu K: Escin: inhibiting inflammation and promoting gastrointestinal transit to attenuate formation of postoperative adhesions. World J Surg 29: 1614-1620, 2005.
17. Bässler D1, Okpanyi S, Schrödter A, Loew D, Schürer M, Schulz HU Bioavailability of beta-aescin from horse chestnut seed extract: comparative clinical studies of two Galenic formulations. *Adv Ther.* 2003 Sep-Oct;20(5):295-304. [PMID: 14964349]
18. Zhou XY, Fu FH, Li Z, *et al.* Escin, a natural mixture of triterpene saponins, exhibits antitumor activity against hepatocellular carcinoma. *Planta Med.* 2009 Dec;75(15):1580-5
19. Pittler MH *et al.* Horse-chestnut seed extract for chronic venous insufficiency. A criteria-based systematic review. *Arch Dermatol.* 1998;134:1356-60

-
20. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. *Cochrane Database Syst Rev*. 2006 Jan 25;(1):CD003230. Review
 21. Carrasco OF1, Vidrio H. Endothelium protectant and contractile effects of the antivaricose principle escin in rat aorta *Vascul Pharmacol*. 2007 Jul;47(1):68-73. Epub 2007 Apr 21. [PMID: 1751226]
 22. Hongsheng Wang, Leiming Zhang, Na Jiang, Zhenhua Wang, Yating Chong *et al*. Anti-inflammatory effects of escin are correlated with the glucocorticoid receptor/NF- κ B signaling pathway, but not the COX/PGF2 α signaling pathway [PMCID: PMC3786821] [PMID: 24137201]
 23. Berti F, Omini C, Longiave D. The mode of action of aescin and the release of prostaglandins. 1977 Aug;14(2):241-9 [PMID: 897216]
 24. Li M1, Lu C, Zhang L, Zhang J, Du Y, Duan S, Wang *Tet al*. Oral Administration of Escin Inhibits Acute Inflammation and Reduces Intestinal Mucosal Injury in Animal Models. *Evid Based Complement Alternat Med*. 2015;2015:503617.
 25. Purnima A, Koti BC, Thippeswamy AH, Jaji MS, Swamy AH, Kurhe YV, *et al*. Antiinflammatory, analgesic and antipyretic activities of *Mimusops elengi* Linn. *Indian J Pharm Sci*. 2010;72:480–5. [PMCID: PMC3013566] [PubMed: 21218059]
 26. Nikajoo L. Analgesic activity of aqueous and alcohol root extracts of *Pergularia daemia* (forsk.) Chiov. *Int J Pharm Pharm Sci*. 2009;1:33–7.
 27. Neeraj Kumar Saini, Manmohan Singhal. Anti-inflammatory, analgesic and antipyretic activity of methanolic *Tecomaria capensis* leaves extract *Asian Pac J Trop Biomed*. 2012 Nov; 2(11): 870–874. [PMCID: PMC3609241] [PMID: 23569863]
 28. Srivastava S, Singh P, Jha KK, Mishra G, Srivastava S, Khosa RL Antiinflammatory, Analgesic and Antipyretic Activities of Aerial Parts of *Costus speciosus* Koen *Indian J Pharm Sci*. 2013 Jan;75(1):83-8. [PMID: 23901165] [PMCID: PMC3719154].